{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:26:59Z","timestamp":1790098019306,"version":"4.0.1"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.coviro.2022.101289","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T16:59:39Z","timestamp":1672246779000},"page":"101289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Advances in the treatment of HTLV-1-associated adult T-cell leukemia lymphoma"],"prefix":"10.1016","volume":"58","author":[{"given":"Adrienne A","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2022.101289_bib1","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/00042560-199600001-00004","article-title":"Adult T-cell leukemia in Japan","volume":"13","author":"Takatsuki","year":"1996","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"10.1016\/j.coviro.2022.101289_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","article-title":"Adult T-cell leukemia: clinical and hematologic features of 16 cases","volume":"50","author":"Uchiyama","year":"1977","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101289_bib3","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","article-title":"Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma","volume":"77","author":"Poiesz","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2022.101289_bib4","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","article-title":"Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease","volume":"79","author":"Yoshida","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2022.101289_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological aspects and world distribution of HTLV-1 infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Front Microbiol"},{"key":"10.1016\/j.coviro.2022.101289_bib6","unstructured":"ECDC Technical Report: Geographical Distribution of Areas with a High Prevalence of HTLV-1 Infection; 2015. Available from: \u3008http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/geographical-distribution-areas-high-prevalence-HTLV1.pdf\u3009. (Accessed 19 June 2022)."},{"key":"10.1016\/j.coviro.2022.101289_bib7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/ijc.2910430618","article-title":"Age- and sex-specific cumulative rate and risk of ATLL for HTLV-I carriers","volume":"43","author":"Kondo","year":"1989","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coviro.2022.101289_bib8","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1586\/1744666X.2014.966690","article-title":"Inflammatory manifestations of HTLV-1 and their therapeutic options","volume":"10","author":"Martin","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.coviro.2022.101289_bib9","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-015-1002-0","article-title":"High prevalence of bronchiectasis is linked to HTLV-1-associated inflammatory disease","volume":"15","author":"Honarbakhsh","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.coviro.2022.101289_bib10","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1126\/science.1080115","article-title":"Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton","volume":"299","author":"Igakura","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.coviro.2022.101289_sbref10","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1809779","article-title":"Risk of Human T-Cell leukemia virus type 1 infection in kidney transplantation","volume":"380","author":"Yamauchi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2022.101289_bib12","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","article-title":"Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma","volume":"15","author":"Ishitsuka","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coviro.2022.101289_bib13","doi-asserted-by":"crossref","DOI":"10.21037\/aol-21-6","article-title":"Adult T-cell leukemia\/lymphoma-pathobiology and implications for modern clinical management","volume":"5","author":"Cook","year":"2021","journal-title":"Ann Lymphoma"},{"key":"10.1016\/j.coviro.2022.101289_sbref13","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2012.00322","article-title":"Adult T-cell leukemia: a review of epidemiological evidence","volume":"3","author":"Iwanaga","year":"2012","journal-title":"Front Microbiol"},{"key":"10.1016\/j.coviro.2022.101289_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.01124","article-title":"Epidemiology of HTLV-1 Infection and ATL in Japan: an update","volume":"11","author":"Iwanaga","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.coviro.2022.101289_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/tropej\/fmx039","article-title":"Early onset of HTLV-1 Associated Myelopathy\/Tropical Spastic Paraparesis (HAM\/TSP) and Adult T-cell Leukemia\/Lymphoma (ATL): systematic search and review","volume":"64","author":"Oliveira","year":"2018","journal-title":"J Trop Pediatr"},{"key":"10.1016\/j.coviro.2022.101289_bib17","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"363","author":"Oshima","year":"2017"},{"key":"10.1016\/j.coviro.2022.101289_bib18","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V99.5.1505","article-title":"Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells","volume":"99","author":"Yoshie","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101289_bib19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.2004.04999.x","article-title":"Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia\/lymphoma cells","volume":"126","author":"Karube","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coviro.2022.101289_bib20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coviro.2022.101289_bib21","doi-asserted-by":"crossref","first-page":"51981","DOI":"10.18632\/oncotarget.10223","article-title":"Adult T-cell leukemia\/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy","volume":"7","author":"Zell","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.coviro.2022.101289_bib22","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1002\/cncr.25147","article-title":"A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia\/lymphoma: a multicenter clinicopathologic experience and new prognostic score","volume":"116","author":"Phillips","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.coviro.2022.101289_bib23","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1080\/10428194.2017.1365862","article-title":"Diagnostic challenges of adult T-cell leukemia\/lymphoma in North America \u2013 a clinical, histological, and immunophenotypic correlation with a workflow proposal","volume":"59","author":"Licata","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.coviro.2022.101289_sbref23","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/bloodadvances.2017011106","article-title":"Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States","volume":"2","author":"Malpica","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.coviro.2022.101289_bib25","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1182\/blood-2012-07-445593","article-title":"HTLV-1-infected T cells contain a single integrated provirus in natural infection","volume":"120","author":"Cook","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101289_bib26","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1182\/blood-2014-02-553602","article-title":"The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia\/lymphoma","volume":"123","author":"Cook","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101289_bib27","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood-2009-12-257410","article-title":"Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan","volume":"116","author":"Iwanaga","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101289_bib28","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/sj.bjc.6605345","article-title":"Mechanisms of HTLV-1 persistence and transformation","volume":"101","author":"Boxus","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.coviro.2022.101289_bib29","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.coviro.2022.101289_sbref29","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1182\/blood.2021013568","article-title":"Whole-genome landscape of adult T-cell leukemia\/lymphoma","volume":"139","author":"Kogure","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101289_sbref30","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood.2019002665","article-title":"Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia\/lymphoma diagnosis","volume":"135","author":"Rowan","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101289_sbref31","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-01-824607","article-title":"North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101289_bib33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/BF02983215","article-title":"Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109)","volume":"77","author":"Tsukasaki","year":"2003","journal-title":"Int J Hematol"},{"key":"10.1016\/j.coviro.2022.101289_bib34","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coviro.2022.101289_bib35","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","article-title":"A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303","volume":"113","author":"Yamada","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coviro.2022.101289_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.21","article-title":"Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma","volume":"6","author":"Ratner","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.coviro.2022.101289_bib37","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coviro.2022.101289_sbref37","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1200\/JCO.18.00501","article-title":"Revised adult T-Cell leukemia-lymphoma international consensus meeting report","volume":"37","author":"Cook","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coviro.2022.101289_bib39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3109\/10428199409049728","article-title":"Clinicopathological features of adult T-cell leukemia with CD30 antigen expression","volume":"15","author":"Ohtsuka","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.coviro.2022.101289_bib40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2022.101289_bib41","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2009-09-242347","article-title":"Long-term study of indolent adult T-cell leukemia-lymphoma","volume":"115","author":"Takasaki","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101289_bib42","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","article-title":"Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes","volume":"28","author":"Bazarbachi","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coviro.2022.101289_sbref42","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens9050342","article-title":"Antiretroviral therapy in HTLV-1 infection: an updated overview","volume":"9","author":"Marino-Merlo","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.coviro.2022.101289_sbref43","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjh.17749","article-title":"Clinical significance of TP53 mutations in adult T-cell leukemia\/lymphoma","volume":"195","author":"Kusumoto","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coviro.2022.101289_bib45","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coviro.2022.101289_bib46","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15123","article-title":"Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation","volume":"184","author":"Ishida","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coviro.2022.101289_bib47","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coviro.2022.101289_sbref47","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3324\/haematol.2018.205096","article-title":"Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed\/refractory adult T-cell leukemia\/lymphoma","volume":"104","author":"Phillips","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.coviro.2022.101289_sbref48","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.3324\/haematol.2019.219253","article-title":"Molecular remissions are observed in chronic adult T-cell leukemia\/lymphoma in patients treated with mogamulizumab","volume":"104","author":"Cook","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.coviro.2022.101289_bib50","doi-asserted-by":"crossref","first-page":"606","DOI":"10.2340\/00015555-2027","article-title":"Stevens-Johnson Syndrome associated with mogamulizumab-induced deficiency of regulatory T cells in an adult T-cell leukaemia patient","volume":"95","author":"Honda","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.coviro.2022.101289_bib51","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","article-title":"Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-Cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality","volume":"34","author":"Fuji","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coviro.2022.101289_bib52","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.bbmt.2016.05.017","article-title":"Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute Graft-versus-Host disease","volume":"22","author":"Sugio","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.coviro.2022.101289_sbref52","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101289_bib54","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clim.2014.09.012","article-title":"Safety, efficacy, and pharmacokinetics\/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia\/lymphoma","volume":"155","author":"Berkowitz","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coviro.2022.101289_bib55","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1078-0432.CCR-16-1022","article-title":"Phase II study of Alemtuzumab (CAMPATH-1) in patients with HTLV-1-associated adult T-cell leukemia\/lymphoma","volume":"23","author":"Sharma","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coviro.2022.101289_bib56","doi-asserted-by":"crossref","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.coviro.2022.101289_bib57","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coviro.2022.101289_bib58","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-Cell leukemia-lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2022.101289_bib59","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood.V93.1.278","article-title":"Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells","volume":"93","author":"Bazarbachi","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101289_sbref59","doi-asserted-by":"crossref","DOI":"10.1186\/s12977-020-0513-y","article-title":"Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia\/lymphoma","volume":"17","author":"Mar\u00e7ais","year":"2020","journal-title":"Retrovirology"},{"key":"10.1016\/j.coviro.2022.101289_bib61","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","article-title":"Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas","volume":"29","author":"Yamagishi","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.coviro.2022.101289_bib62","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-144676","article-title":"A Global Phase 2 Study of Valemetostat Tosylate (Valemetostat) in patients with Relapsed or Refractory (R\/R) Peripheral T-Cell Lymphoma (PTCL), including R\/R Adult T-Cell Leukemia\/Lymphoma (ATL) \u2013 Valentine-PTCL01","volume":"138","author":"Foss","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101289_bib63","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.coviro.2022.101289_bib64","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11912-011-0186-8","article-title":"Newly emerging therapies targeting viral-related lymphomas","volume":"13","author":"Ramos","year":"2011","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.coviro.2022.101289_sbref64","doi-asserted-by":"crossref","DOI":"10.3390\/v13081461","article-title":"An epitope platform for safe and effective HTLV-1-immunization: potential applications for mRNA and peptide-based vaccines","volume":"13","author":"Lucchese","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2022.101289_bib66","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1182\/blood-2016-09-739433","article-title":"The Global Virus Network\u2019s Task Force on HTLV-1; Screening transplant donors for HTLV-1 and -2","volume":"128","author":"Gallo","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101289_sbref66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1473-3099(18)30735-7","article-title":"Towards the elimination of HTLV-1 infection in Japan","volume":"19","author":"Nishijima","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2022.101289_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2019.00999","article-title":"Mother-to-child HTLV-1 transmission: unmet research needs","volume":"10","author":"Rosadas","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.coviro.2022.101289_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.00979","article-title":"Strategies of HumanT-Cell Leukemia Virus Type 1 for Persistent Infection: Implications forLeukemogenesis of Adult T-Cell Leukemia-Lymphoma","volume":"11","author":"Yasunaga","year":"2020","journal-title":"Front Microbiol"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625722001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625722001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:06:11Z","timestamp":1761818771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625722001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":69,"alternative-id":["S1879625722001006"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2022.101289","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the treatment of HTLV-1-associated adult T-cell leukemia lymphoma","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2022.101289","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101289"}}